-

Savara Announces Participation in the Upcoming Citizens Life Sciences Conference

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will be hosting 1x1 meetings and participating in a fireside chat at the Citizens Life Sciences Conference on Thursday, May 8, 2025 at 10:30am EST/7:30am PST.

The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website at https://savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com, and LinkedIn.

*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.

Contacts

Media and Investor Relations Contact
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
ir@savarapharma.com

Industry:

Savara Inc.

NASDAQ:SVRA
Release Versions
English

Contacts

Media and Investor Relations Contact
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
ir@savarapharma.com

More News From Savara Inc.

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and security agreement with Hercules Capital, Inc. (NYSE:HTGC), strengthening its balance sheet and liquidity. Under the terms of the amended loan agreement, up to an additional $75 million will become available upon FDA’s approval of MOLBREEVI, the Company’s investigational therapy in autoimmune pul...

Savara Announces New Employment Inducement Grant

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On January 15, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 17,500 shares of the Company’s common stock and restrict...

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

LANGHORNE, Pa.--(BUSINESS WIRE)--PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced an exclusive distribution agreement for MOLBREEVI. Savara submitted the MOLBREEVI BLA to the U.S. Food and Drug Administration (FDA) in December 2025 for the treatment of autoimmune PAP. Priority Review was req...
Back to Newsroom